Twist Bioscience (NASDAQ:TWST) Trading Down 2.4% - Time to Sell?

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) shares were down 2.4% during mid-day trading on Wednesday . The company traded as low as $45.01 and last traded at $45.22. Approximately 110,130 shares changed hands during trading, a decline of 89% from the average daily volume of 966,651 shares. The stock had previously closed at $46.31.

Analysts Set New Price Targets

TWST has been the topic of several research reports. Barclays dropped their target price on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. The Goldman Sachs Group increased their price objective on Twist Bioscience from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, July 9th. Robert W. Baird lifted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. Finally, Evercore ISI lifted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $51.63.

Twist Bioscience Stock Down 2.7 %

The business's 50 day moving average is $43.91 and its 200-day moving average is $44.20.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same quarter in the previous year, the firm posted ($1.01) earnings per share. The company's revenue for the quarter was up 27.7% on a year-over-year basis. Equities analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total value of $124,960.34. Following the completion of the sale, the chief operating officer now directly owns 171,212 shares of the company's stock, valued at $9,694,023.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the company's stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total value of $124,960.34. Following the completion of the transaction, the chief operating officer now owns 171,212 shares of the company's stock, valued at $9,694,023.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam Laponis sold 856 shares of the firm's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the completion of the sale, the chief financial officer now owns 73,397 shares of the company's stock, valued at $3,068,728.57. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,246 shares of company stock worth $1,829,356 over the last three months. 3.92% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $526,000. Principal Financial Group Inc. raised its stake in Twist Bioscience by 151.2% during the first quarter. Principal Financial Group Inc. now owns 39,624 shares of the company's stock worth $1,360,000 after acquiring an additional 23,850 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Twist Bioscience by 12.1% during the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company's stock valued at $42,116,000 after acquiring an additional 132,770 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Twist Bioscience by 30.7% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 156,288 shares of the company's stock valued at $5,362,000 after purchasing an additional 36,744 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Twist Bioscience by 34.8% in the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company's stock worth $5,895,000 after purchasing an additional 44,349 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.